Results from the Oxford/AstraZeneca phase 3 vaccine trial are expected by the end of the month. Hopes are high following the announcement that a second vaccine, developed by Moderna, appears to be 95% effective. The findings come just a week after Pfizer released similarly impressive data. The good news keeps on coming.